Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

1,088

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Multiple Sclerosis
Interventions
DRUG

Teriflunomide

"Film-coated tablet~Oral administration"

DRUG

Placebo (for teriflunomide)

"Film-coated tablet~Oral administration"

Trial Locations (21)

08807

Sanofi-Aventis, Bridgewater

Unknown

Sanofi-Aventis Austria, Vienna

sanofi-aventis, Canada, Laval

Sanofi-Aventis, Santiago

Sanofi-Aventis Administrative Office, Prague

sanofi-aventis Denmark, Hørsholm

Sanofi-Aventis Administrative Office, Tallinn

sanofi-aventis Finland, Helsinki

sanofi-aventis France, Paris

Sanofi-Aventis Deutschland GmbH, Berlin

Sanofi-Aventis, Milan

Sanofi-Aventis, Gouda

Sanofi-Aventis, Lysaker

sanofi-aventis Poland, Warsaw

Sanofi-Aventis, Porto Salvo

Sanofi-Aventis, Moscow

Sanofi-Aventis, Bromma

Sanofi-Aventis Switzerland, Geneva

sanofi-aventis Turkey, Istanbul

Sanofi-Aventis Administrative Office, Kiev

sanofi-aventis UK, Guildford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY